Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|October 1, 2020
Additive manufacturing technologies enabling rapid and interventional production of protective face shields and masks during the COVID-19 pandemicJędrzej Wierzbicki, Maciej Nowacki, Marta Chrzanowska, et al.Journal of Cellular and Molecular Medicine|October 23, 2019
Expression level of EGFR and MET receptors regulates invasiveness of melanoma cellsKatarzyna Pietraszek-Gremplewicz, Aleksandra Simiczyjew, Ewelina Dratkiewicz, et al.Postepy Dermatologii I Alergologii|August 7, 2023
Incidence of different types of cancer in the follow-up period after primary diagnosis and treatment of melanoma. Single-centre 4-year follow-up on a population of 709 patientsMarcin Ziętek, Jędrzej Wierzbicki, Maciej Nowacki, et al.International Journal of Molecular Sciences|October 23, 2021
Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma TreatmentAdam Bieniek, Marek Wiśniewski, Joanna Czarnecka, et al.Central-European Journal of Immunology|October 30, 2023
Severe complications of nivolumab monotherapy in an adolescent with malignant melanomaAleksandra Grzegorczyk, Zuzanna Marczyńska, Rafał Matkowski, et al.Cell Communication and Signaling : CCS|May 10, 2022
Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblastsJustyna Mazurkiewicz, Aleksandra Simiczyjew, Ewelina Dratkiewicz, et al.Cell Communication and Signaling : CCS|September 19, 2022
Melanoma stimulates the proteolytic activity of HaCaT keratinocytesJustyna Mazurkiewicz, Aleksandra Simiczyjew, Ewelina Dratkiewicz, et al.Postepy Dermatologii I Alergologii|January 23, 2023
Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapiesMarcin Ziętek, Marcin Zdzienicki, Jędrzej Wierzbicki, et al.Contemporary Oncology (Poznan, Poland)|July 7, 2025
Chemotherapy efficacy in advanced melanoma patients after failure of immune checkpoint and BRAF/MEK inhibitorsŁukasz Galus, Daria Tusień Małecka, Michał Michalak, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 23, 2020
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practicePiotr Rutkowski, Marcin Ziętek, Bożena Cybulska-Stopa, et al.Pageof 5